Members of the People Living with HIV group protesting outside the residence of Union Health Minister J.P Nadda. | Photo Credit: Vidya Krishnan
Source: The Hindu, March 9, 2017
Members of the People Living with HIV group protested outside the residence of Union Health Minister J.P Nadda, demanding the deletion of the term ‘as far as possible’ from the HIV/AIDS (Prevention and Control) Bill.
The crucial public health legislation, aimed to guarantee rights to India’s 2.4 million strong HIV community, was approved by the Cabinet in October and immediately rejected by the HIV networks, as the phrase ‘as far as possible’ left it entirely open to interpretation. Continue reading
A lack of innovation in diagnostics is making Indians more prone to drug-resistant TB, which is difficult to treat and could be fatal.
By Ankur Paliwal, The Wire | March 3, 2017
The end of an otherwise typical day in the winter of 2013 would mark the beginning of a hard and lonely battle for 18-year-old Janki Patil (name changed). She woke up in her 100 square foot poorly ventilated one-room house. Her brother and mother – both sick with tuberculosis – were still asleep, on the floor, next to her father, younger sister and grandmother. Continue reading
HIV positive children walk to the wash basin with their plate after eating lunch at a school for HIV/AIDS-infected children in Bhugaon, some 130 km (81 miles) from Mumbai, January 9, 2008. Photo Credit: Reuters
By Indirani Basu, HuffPost India | March 6, 2017
NEW DELHI — Thousands of children living with HIV in India are reported to be at risk because the country has run out of Lopinavir syrup, a child-friendly HIV drug. The only manufacturer of the drug, Cipla, has not been paid by the Indian health ministry since 2014, reported The Hindu. Continue reading
Source: Scroll, March 6, 2017
The pharma company has stopped production of the Lopainavir syrup saying it has not recovered its dues from the government.
As many as 637 children living with HIV have written to Prime Minister Narendra urging him to look into an alleged delay in payments to pharmaceutical company Cipla, which has led to the firm discontinuing a life-saving drug. The company has stopped producing the Lopinavir syrup citing “delay in payments by the national programme for the HIV medicines by several years and even non-payment of its dues in many cases”, reported The Hindu. Continue reading
By Vidya Krishnan, The Hindu | March 6, 2017
Cipla, sole manufacturer of Lopinavir syrup, stopped production of the drug after govt. failed to clear dues
Desperate over withdrawal of a life saving drug, children living with HIV (CLHIV) have written to Prime Minister Narendra Modi for help.
The letter, written on March 4, is signed by 637 children ranging from ages 3 to 19 and states that, “the pharmaceutical company Cipla has in various forums cited delay in payments by the national programme for the HIV medicines by several years and even non-payment of its dues in many cases. Profits on child doses of HIV medicines are small and delayed payments are having a chilling effect on the ability of the National AIDS Control Organisation (NACO) to convince the company to participate in the bids it invited annually.”
Dear Prime Minister Modi, Minister Jaitley and Minister Nadda,
Developing a proactive approach to the prevention of HIV medicines shortages
Shortages of medicines have been a global problem for the past decade and have also increasingly affected the National AIDS Control Programme in India. We, as people living with HIV, have consistently worked together with the national programme to address shortages and stock outs as it is our community which faces delayed or interrupted treatment, increasing the risk of developing resistance to their current regimen. Continue reading